{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:31:42Z","timestamp":1759336302504,"version":"3.40.5"},"reference-count":32,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["RMHP"],"DOI":"10.2147\/rmhp.s301724","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T10:40:07Z","timestamp":1633344007000},"page":"4155-4168","source":"Crossref","is-referenced-by-count":2,"title":["Tapentadol and Oxycodone\/Naloxone Prescribing Patterns in Primary Health Care in Catalonia, Spain: A Cross-Sectional Study"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Montserrat","family":"Vi\u00f1as-Bastart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00edriam","family":"Oms-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0frica","family":"Pedraza-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-5968","authenticated-orcid":true,"given":"Irene","family":"Lizano-D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4386-9315","authenticated-orcid":true,"given":"Eduardo L","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-6285","authenticated-orcid":true,"given":"Pilar","family":"Modamio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/1471-2458-11-770","volume":"11","author":"Goldberg","year":"2011","journal-title":"BMC Public Health"},{"key":"ref3","unstructured":"International Association for the Study of Pain (IASP). European Federation of IASP Chapters. Right to pain relief. 4A. Unrelieved pain is a major global healthcare problem; 2004. Available from: https:\/\/www.iasp-pain.org\/GlobalYear\/RighttoPainRelief. Accessed April 20, 2021."},{"key":"ref4","first-page":"1001","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur J Pain"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/pme.12640","volume":"16","author":"Due\u00f1as","year":"2015","journal-title":"Pain Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1185\/03007995.2014.921610","volume":"30","author":"Provenzano","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"ref8","first-page":"CD012509","volume":"10","author":"Els","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","volume":"20","author":"Manchikanti","year":"2017","journal-title":"Pain Physician"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/JPR.S160255","volume":"11","author":"Meske","year":"2018","journal-title":"J Pain Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejp.1196","volume":"22","author":"Faria","year":"2018","journal-title":"Eur J Pain"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s12325-019-00932-7","volume":"36","author":"Morgan","year":"2019","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jpain.2008.06.014","volume":"9","author":"Vondrackova","year":"2008","journal-title":"J Pain"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jpainsymman.2017.07.025","volume":"54","author":"Huang","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"ref15","unstructured":"The Spanish Agency of Medicines and Medical Devices (AEMPS). Summary of Product Characteristics tapentadol (Palexia retard\u00ae, Gr\u00fcnenthal pharma, S.A). Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/75917\/FT_75917.html. Accessed May 20, 2019."},{"key":"ref16","unstructured":"The Spanish Agency of Medicines and Medical Devices (AEMPS). Summary of Product Characteristics oxycodone\/naloxone (Targin\u00ae, Mundipharma pharmaceuticals, S.L.). Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/71124\/FT_71124.html. Accessed May 20, 2019."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/pm\/pnx159","volume":"19","author":"Vi\u00f1as-Bastart","year":"2018","journal-title":"Pain Med"},{"key":"ref18","unstructured":"Government of Catalonia. Department of Health. Organization Chart: unit of coordination and strategy of the medicine; 2019. Available from: http:\/\/www14.gencat.cat\/sacgencat\/AppJava\/organigrama.jsp?codi=10137&jq=200001. Accessed December 20, 2020."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clin Drug Investig"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/papr.12361","volume":"16","author":"Baron","year":"2016","journal-title":"Pain Pract"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40634-019-0204-6","volume":"6","author":"D\u2019Amato","year":"2019","journal-title":"J Exp Orthop"},{"volume-title":"StatPearls","year":"2021","key":"ref22"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2021.03.001","author":"Zhang","year":"2021","journal-title":"J Pain"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","volume":"111","author":"Bartley","year":"2013","journal-title":"Br J Anesth"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2147\/JPR.S94650","volume":"11","author":"Packiasabapathy","year":"2018","journal-title":"J Pain Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ejp.970","volume":"21","author":"O\u2019Brien","year":"2017","journal-title":"Eur J Pain"},{"key":"ref27","unstructured":"Canadian Agency for Drugs and Technologies in Health. Long-acting opioids for chronic non-cancer pain: a review of the clinical efficacy and safety; 2015. Available from: https:\/\/cadth.ca\/sites\/default\/files\/pdf\/htis\/aug-2015\/RC0698%20Opioids%20Final.pdf. Accessed June 20, 2020."},{"key":"ref28","unstructured":"Agency for Healthcare Research and Quality (AHRQ). Opioid Treatments for Chronic Pain. Comparative Effectiveness Review No. 229. AHRQ Publication No. 20-EHC011; 2020. Available from: https:\/\/effectivehealthcare.ahrq.gov\/sites\/default\/files\/pdf\/opioids-chronic-pain.pdf. Accessed June 20, 2021."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e1009428","DOI":"10.1371\/journal.pgen.1009428","volume":"17","author":"Johnston","year":"2021","journal-title":"PLoS Genet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.japh.2018.09.005","volume":"59","author":"Hadlandsmyth","year":"2019","journal-title":"J Am Pharm Assoc"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ejp.1496","volume":"24","author":"Bialas","year":"2020","journal-title":"Eur J Pain"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/acem.13934","volume":"27","author":"Wong","year":"2020","journal-title":"Acad Emerg Med"}],"container-title":["Risk Management and Healthcare Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=74284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=74284","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T10:40:36Z","timestamp":1633344036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/tapentadol-and-oxycodonenaloxone-prescribing-patterns-in-primary-healt-peer-reviewed-fulltext-article-RMHP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2147\/rmhp.s301724","relation":{},"ISSN":["1179-1594"],"issn-type":[{"type":"electronic","value":"1179-1594"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}